Project Grant R01HL187968
Award Date 8/1/26
Completion Date 6/30/31
Dollars Obligated $743K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Madison, WI 53715, USA
Similar Awards
- The National Heart, Lung, and Blood Institute, under the Department of Health and Human Services National Institutes of Health, awarded The Washington University $768,128 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to mechanistically evaluate the role of oscillatory shear stress in deep vein thrombosis prevention. The recipient will conduct in vitro, in vivo, and human model studies to determine whether restoration of oscillatory shear stress in veins...
- The National Heart, Lung, and Blood Institute awarded the University of Washington $1.608 million on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate genomic and proteomic determinants of recurrent venous thromboembolism. The research addresses the high rate of recurrent venous thromboembolism (VTE) events—either deep vein thrombosis or pulmonary embolism—occurring in 20–30% of survivors within five years. Current anticoagulant therapies, while...
- The National Heart, Lung, and Blood Institute awarded Versiti Blood Health, Inc. $1,069,072 on March 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to decode kindlin-3 signaling in platelets and neutrophils. The research investigates the regulatory role of kindlin-3, a critical signaling adaptor in hematopoietic cells, in thrombosis and inflammation. The project focuses on elucidating molecular mechanisms by which kindlin-3 regulates platelet activation during...
- The National Heart, Lung, and Blood Institute awarded Yale University $577,016 under the Cardiovascular Diseases Research program (CFDA 93.837) on September 1, 2026, to support research into the molecular mechanisms underlying endothelial von Willebrand factor exocytosis. The research addresses how von Willebrand factor (VWF), a multifunctional plasma glycoprotein essential to hemostasis and thrombosis, is mobilized from vascular stores in endothelial cells. VWF is synthesized and stored in...
- The National Heart, Lung, and Blood Institute, a component of the Department of Health and Human Services National Institutes of Health, awarded $697,198 to the University of Texas at Austin on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate sex-biased integrin-mediated endothelialization processes for precision vascular graft design. The recipient is conducting research to identify how biological sex affects endothelial cell behavior in response...
- The National Heart, Lung, and Blood Institute awarded the University of Wisconsin – Madison $521,101 on June 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of macrophages and hematopoietic stem cell trogocytosis in the bone marrow niche. The research defines mechanisms by which hematopoietic stem cells acquire macrophage-associated markers through trogocytosis—rapid transfer of membrane-bound proteins from adjacent cells—and examines how this...
- The National Heart, Lung, and Blood Institute awarded the University of Illinois $1.6 million under the Cardiovascular Diseases Research program (CFDA 93.837) on September 1, 2026, to investigate GA12-dependent mechanisms of basal and regulated endothelial cell von Willebrand factor (VWF) secretion. This is a Project Grant (R01HL186410). The research addresses microvascular thrombotic occlusions in inflammatory conditions such as sepsis and sickle cell disease, where elevated VWF plasma levels...
- The National Heart Lung and Blood Institute awarded The Johns Hopkins University $175,874 on July 6, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a prospective, three-center cohort study investigating clinical risk factors and biomarkers for recurrent venous thromboembolism in children with cardiac disease. The research addresses the elevated risk of recurrent VTE events—including deep vein thrombosis and pulmonary embolism—in children with congenital and...
- The National Heart, Lung, and Blood Institute awarded the Scripps Research Institute $1,101,338 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to engineer noncovalent antibody-enzyme thrombolytic complexes that function orthogonally to the natural hemostatic system. The project, R01HL184492, addresses limitations of current plasminogen activator therapies—including narrow therapeutic window, contraindications, and risks of neurotoxicity, bleeding, and...
- The National Heart, Lung, and Blood Institute awarded New York University $872,787 on August 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct proteomic discovery and validation research on chronic limb-threatening ischemia (CLTI), the most severe form of peripheral artery disease. The award funds development of proteomic signatures to predict major adverse limb events (MALE) and major adverse cardiovascular events (MACE) in CLTI patients, and to guide...